Fluidx Medical Technology, Inc. released details on the clinical use of their GPX Embolic Device for blocking flow to small microvasculature and large tumor feeding vessels.
Andrew Holden, M.D., MBChB, FRANZCR, EBIR, ONZM, Director of Interventional Radiology, Auckland City Hospital, Auckland, New Zealand, said: “The versatility of the GPX product has been demonstrated in a variety of interventional oncology uses. We have seen excellent distal penetration and backfilling of larger vessels in our tumor cases.”
The GPX Embolic Device is an innovative embolic, designed to combine the benefits of other embolics like coils, particles, and liquids with simplified preparation, delivery, precision, and control leading to durable, long-term occlusions. GPX technology is a low viscosity, aqueous-based solution in a syringe that solidifies into a durable embolic material upon delivery without polymerization or dimethyl-sulfoxide (DMSO) precipitation.
Dr. Martin Krauss, M.D., Head of Interventional Radiology, Christchurch Hospital, Christchurch, New Zealand, said: “We saw excellent filling of the distal branches and complete tumor devascularization. The patient exhibited a marked decrease in hematuria (blood in urine) following the procedure. Since we were not worried about catheter entrapment, we could take our time and ensure that we occluded all the feeding vessels of the tumor.”
GPX is packaged ready-to-use in a syringe, requires less than 1 minute of tableside preparation by the clinician, and may be delivered through standard catheters or microcatheters.* Clinicians can decide at the time of care to use GPX alone or as a complement to coils or other embolic technologies.
Libble Ginster, CEO, Fluidx Medical Technology, USA, said: “GPX is a highly versatile product that has been shown to successfully occlude small microvasculature as well as the larger tumor feeding vessels. GPX can be delivered using very small microcatheters, designed to give physicians the flexibility to be highly targeted and thorough in devascularizing tumors.”
The GPX Embolic Device is under development and does not have marketing clearance or approval in any market for now.
